Epstein-Barr virus (EBV) is one of the most widespread human viruses, with over 80% of the general population exposed by young adulthood, as determined by antibody studies. Initial infection usu­ ally occurs during childhood or the teenage years. It is clear that, de­ pending on the age of the recipient, clinical manifestations of the primary infection can vary. It has been known for 20 years that EBV is the etiologic agent of acute infectious mononucleosis (IM) and is also closely associated with African Burkitt's lymphoma (BL) and naso­ it is a pharyngeal carcinoma (NPC). There is increasing evidence that factor in the etiology of B-celllymphomas, which arise at a high fre­ quency in immunodeficient populations. EBV may also contribute to the development of autoimmune disease. Thus, this virus continues to attract world-wide attention. The major target cell for EBV infection has now been conclusively identified as the complement receptor-type 2 (CR2), the Cd/Cdg 3 3 receptor on B lymphocyte. It is apparent, however, that other cells also can become infected by EBV, such as epithelial cells in the parotid gland and other epithelial cells in the upper respiratory tract. This might help account for the EBV-assodated carcinomas of the upper respiratory tract. The first in a series of international symposia on EBV -associated diseases focused primarily on Burkitt's-type lymphomas or on NPC (Kyoto 1977; Dusseldorf 1980; Kuala Lumpur 1982) and emphasized mainly the clinical elements of these diseases. Subsequent symposia (Loutraki, 1984; St.

Inhalt

I. Cellular and Molecular Biology of EBV.- Epstein-Barr Virus Transformation of B Lymphocytes: Molecular Pathogenesis.- Role of the ZEBRA Protein in the Switch Between Epstein-Barr Virus Latency and Replication.- DNA:EBNA-1 Interactions and Latency of Epstein-Barr Virus.- The EBV DR Enhancer Contains Two Functionally Different Domains: A and B.- Identification of the Gene Product Encoded by the notl Repeats of the Genome.- Effect of the BZLF 1 Transactivator on Different Classes of EBV Promoters.- EBNA Expression and CpG Methylation of Viral DNA in EBV Associated Tumors.- Transcription and Protein Expression Pattern of EBV in Freshly Infected Lymphoid Cells.- Characterization of a cDNA of Epstein-Barr Virus DNase Gene.- The 5' Flanking Region of the Gene for EBNA-2 Contains a Cell Type Specific cis-Acting Regulatory Element that Activates Transcription in Transfected B-Cells.- Establishment and Characterization of a Tumor Cell Line from Nasopharyngeal Carcinoma Tissue.- II. Molecular Pathobiology of EBV Infections.- EBV DNA Structure and Expression in EBV-Induced Proliferations.- The Role of Differentially Expressed EB-Viral and Cellular Genes for Development of Virus-Related Tumors and Possibilities of the Control of These Diseases.- Detection of Proteins Binding to the EBV EBNA-2 Promoter.- Anti EBNA-1 Protein Induced with TPA.- Characterization of the EBV Alkaline Exonuclease Expressed in a Recombinant Prokaryotic System.- Immunocytochemistry of EBV Envelope Glycoproteins on Freeze-Fractured Nuclear 125 Membranes of Virus Producer Cells.- Detection of a Transformation-Incompetent Epstein-Barr Virus Genotype in a Seronegative Host.- Propagation and Cytogenetic Analysis of NPC Biopsies in Nude Mice: Evidence for a Translocation in Chromosome #8 AT 8q 24, Which Is the Localization of the c-myc Gene.- Epstein-Barr Virus Gene Expression in Lymphomas Induced by the Virus in the Cottontop Tamarin.- The DNA Demethylating Agent 5-Azacytidine Induces the Expression of EBNA 2-6 and LMP in Burkitt Lymphoma Lines.- Epstein-Barr Virus mRNA Expression in Biopsies of Lymphoma Induced by the Virus in Cottontop Tamarin.- Establishment of Salivary Gland Epithelial Cell Lines from Patients with Sjogren's Syndrome and Normal Individual.- The Transforming Activity of a Nasopharyngeal Carcinoma-Derived Epstein-Barr Virus Isolate.- III. Immunological Aspects of EBV Infections.- Immune Control Mechanisms over EBV Infection.- Epstein-Barr Virus Infection and Immunoregulation.- Helper T Lymphocyte Proliferation is Stimulated by the Presence of EBV-Carrying B Lymphocytes.- Role of the Recognition of Virion Antigens in the T-Cell Mediated Inhibition of EBV-Induced B-Cell Transformation.- An Analysis of the Cytotoxic T-Cell Response of A- and B- Type EB Virus.- The Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 (EBNA-1) in Autoimmunity: B and T Cell Epitopes.- Cytotoxic Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma.- Generation of Cytotoxic T Cells Against EBV Infected B Lymphocytes.- T Cell Response to Peptides Encompassing a 5 Amino Acid Sequence Shared by the HLA DW4 DR Beta 1 Chain and the Epstein-Barr Virus Glycoprotein gp 110.- Growth Stimulation and Immunoglobulin (Ig) Secretion in Epstein-Barr Virus (EBV) Infected B Cells by Interleukin 6 (IL-6).- Presence of EBV Infected Cells in the Bone Marrow from Transplant Donors.- IV. Clinical Syndromes Associated with EBV Infections.- Clinical Syndromes Associated with Epstein-Barr Virus.- The Natural History and Treatment of EBV Infections and Their Nonmalignant Complications.- Epstein-Barr Virus Polymorphic Diffuse Lymphoma Associated with Leukemia and with Congenital Immunodeficiencies.- EB-Viral Expression Depends on the Differentiated Status of Epithelial Cells in Oral Hairy Leukoplakia.- EBV-Associated Lymphoproliferative Disorders in a Large Transplant Population.- EBV-Associated Head and Neck Tumours and Thymic Lesions.- Expression of EBV in the Nasopharyngeal Carcinoma-Derived Nude Mouse Tumour, C15.- Killer Cell Defect and Lack or Loss of Antibodies to Epstein-Barr Virus Glycoproteins in Chronic Active EBV.- Characterization of Cell Types and EBV Gene Expression in Lymphoproliferative Diseases (LPD) of Patients Receiving Bone Marrow Transplants (BMT) after T-Cell Depletion.- Epstein-Barr (EBV) Viral DNA in Tissues of Immunocompetent and Immunodeficient Children.- Different Cell Susceptibility to Epstein-Barr Virus Infection in a Patient with X-linked Lymphoproliferative Syndrome.- V. Diagnosis, Prevention, and Treatment of FSV-Associated Diseases.- Detection of EBV Specific IgA Antibodies to EA, MA, and EBNA-1 Recombinant Proteins in NPC Patients and Controls.- Challenges in the Treatment of EBV-Associated Diseases: New Approaches.- Epstein-Barr Virus Replication and Gene Expression in Oral "Hairy" Leukoplakia.- Changes in Virus-Host Genome Relationship in Two Sublines of the Same Burkitt's Lymphoma.- Molecular Weight Variation of EBNAs as a Means to Identify Different Epstein-Barr Virus Isolates (EBNotyping).- Cell-Mediated Responses to Epstein-Barr Virus Lytic Antigens.- Successful Therapy for EBV Associated B Cell Lymphoproliferative Disorders in Immunodeficiency Using Alpha Interferon and Intravenous Immunoglobulin.- Serological Correlation of HHV-6 and EBV Infections in Infectious Mononucleosis.- Natural Epstein-Barr Virus Isolates from Southern China and California Differ in the Bam H1I Region.- Antibodies Against EBNA-1 Derived Synthetic Peptide in Various Patient Groups.- Nasopharyngeal Carcinoma (NPC): The Influence of Different Types of Interferon (IFN) on Peripheral Blood Lymphocytes.- Early Diagnosis of Nasopharyngeal Carcinoma: A Multipronged Approach.- VI. Special Topics.- Cellular Receptors for Epstein-Barr Virus.- The Post-Infectious Chronic Fatigue Syndrome.- Post Viral Chronic Fatigue Syndrome: Persistence of Epstein-Barr Virus DNA in Muscle.- The Post-Infectious Chronic Fatigue Syndrome: Cell Surface Expression of LFA-1 and ICAM-1.- VII. Possible Cofactors in the Etiology of EB.- Epstein-Barr Virus (EBV)-Induced Transformation and EBV Genome Reorganization in Lymphoblastoid Cell Lines Established from Patients with AIDS Following Enhancement with Chemical Carcinogens.- Human Herpesvirus-6 (Human B Lymphotropic Virus).- Interactions of Epstein-Barr Virus with Human Retroviruses.- An Environmental Plant…